Partnerships
Since our inception in 2002, we have formed more than 40 different relationships with major pharmaceutical companies, other biotechnology companies, the government, and foundations.
Licensing
As a testament to the strength of our leading intellectual property (IP) estate, we believe more than 50% of all clinical-stage RNAi therapeutics are licensed under Alnylam IP, and more than 75% of sales of RNAi products in the research reagent market are covered under Alnylam IP.
About RNAi
With RNAi technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Patent Estate
Alnylam's intellectual property (IP) estate includes issued or granted fundamental patents in the world's major pharmaceutical markets that claim the broad properties of synthetic RNAi therapeutic products. Our IP can be categorized into three areas:
- Fundamental IP required for all siRNA therapeutics
- Chemistry IP required to introduce drug like properties; and Delivery IP related to direct or systemic delivery of siRNA into diseased tissues
- Target IP related to siRNAs for specific disease targets
United States
- US 5,898,031: Crooke - PDF
- US 6,107,094: Crooke - PDF
- US 7,432,250: Crooke - PDF
- US 7,695,902: Crooke - PDF
- US 6,506,559: Fire and Mello - PDF
- US 7,056,704: Tuschl II - PDF
- US 7,078,196: Tuschl II - PDF
- US 10,560,336: Woppmann - PDF
European Union
- EP 928290: Crooke - PDF
- EP 1550719: Kreutzer-Limmer - PDF
- EP 1214945: Kreutzer-Limmer - PDF
- EP 1407044 Tuschl II - PDF
- EP 1309726 Tuschl I - PDF
Japan
United States
- US 5,486,603: Buhr - PDF
- US 6,476,205: Buhr - PDF
- US 5,859,221: Cook - PDF
- US 6,153,737: Manoharan - PDF
- US 7,078,196: Tuschl II - PDF
- US 6,858,225: Semple - PDF
- US 5,976,567: Wheeler - PDF
- US 6,534,484: Wheeler - PDF
- US 6,586,410: Wheeler - PDF
- US 6,815,432: Wheeler - PDF
- US 6,858,224: Wheeler - PDF
- US 12/813,448: Chen (NOA) PDF
- 150 issued patents in-licensed from Isis - PDF
United Kingdom
- UK 2417727: Woppmann - PDF
To review the complaint for patent infringement against Tekmira Pharmaceuticals click here
